drugset / Trial / NCT02659514
Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to establish the dose regimen and evaluate the preliminary efficacy and the safety/tolerability of poziotinib in participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have received at least two prior HER2-directed treatment regimens.
Timeline
- Start
- 2016-02-22
- Primary completion
- 2020-03-11
- Completion
- 2020-03-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Poziotinib | Small molecule | 16 mg | Oral |
| Subject | Poziotinib | Small molecule | 24 mg | Oral |